Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies.

Antiphospholipid (aPL) antibodies include anticardiolipin (aCL) and lupus anticoagulant (LA) antibodies. LA antibodies recognize the complex of lipid-bound (human) prothrombin, in this way inhibiting the phospholipid-dependent coagulation reactions, whereas aCL antibodies are directed towards beta 2-glycoprotein I (beta 2-GPI) bound to an anionic lipid surface. According to their behavior in coagulation reactions, we have divided aCL antibodies into two groups: aCL-type A, which inhibit the phospholipid-dependent coagulation reactions because they enhance the binding of beta 2-GPI to the procoagulant phospholipid surface; and aCL-type B antibodies, which are devoid of anticoagulant properties. We report the distinctive laboratory and clinical profiles of 25 patients with well-characterized, phospholipid-dependent inhibitor of coagulation. Fourteen patients had LA antibodies (aCL-type B were concomitantly present in 10 cases, while in the other four, aCL titer was normal), and the other 11 had aCL-type A antibodies. The laboratory evaluation of the two groups showed the dilute Russell viper venom time (dRVVT) to be the most abnormal coagulation test in the aCL-type A-positive group, whereas the kaolin clotting time (KCT) was the most abnormal assay in the LA-positive group. In fact, the ratios of the coagulation times of patient plasma over normal pooled plasma (mean +/- standard deviation) for LA versus aCL-type A antibodies were 1.48 +/- 0.27 versus 2.20 +/- 0.42, P = .0001, and 2.22 +/- 0.42 versus 1.50 +/- 0.42, P = .0003, for the dRVVT and KCT, respectively. No differences were observed either in the ratios of the activated partial thromboplastin times and the prothrombin times or the plasma levels of beta 2-GPI and prothrombin. Conversely, aCL titers were significantly higher in aCL-type A-positive patients (147 +/- 44 U) than in the LA-positive group (61 +/- 55 U; P = .0003). We ruled out the possibility that platelet contamination of plasma could account for the observed coagulation profiles, as the two patterns were reproduced in platelet-free plasma. In addition, we performed clotting tests in plasma in the presence of phospholipids and calcium after addition of factor IXa or factor Xa. The assay performed with factor Xa was more sensitive to the presence of aCL-type A antibodies, while the assay performed with factor IXa was preferentially sensitive to LA-containing plasmas, supporting the earlier findings with the dRVVT and KCT assays.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  S. Rapaport,et al.  Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. , 1994, Blood.

[2]  Y. Komiyama,et al.  β2-Glycoprotein I and Anticardiolipin Antibody Influence Factor Xa Generation but not Factor Xa Binding to Platelet-Derived Microparticles , 1994, Thrombosis and Haemostasis.

[3]  G. Buchanan,et al.  Hypoprothrombinemia and severe hemorrhage associated with a lupus anticoagulant. , 1993, The Journal of pediatrics.

[4]  P. Hogg,et al.  Anticardiolipin Antibodies Block the Inhibition by β2-Glycoprotein I of the Factor Xa Generating Activity of Platelets , 1993, Thrombosis and Haemostasis.

[5]  T. Barbui,et al.  Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet‐derived microvesicles , 1993, British journal of haematology.

[6]  E. de Benedetti,et al.  No Increase of β2-Glycoprotein I Levels in Patients with Antiphospholipid Antibodies , 1992, Thrombosis and Haemostasis.

[7]  T. Barbui,et al.  Anticoagulant Activity of β2-Glycoprotein I Is Potentiated by a Distinct Subgroup of Anticardiolipin Antibodies , 1992, Thrombosis and Haemostasis.

[8]  H. Moutsopoulos,et al.  Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and β2‐glycoprotein‐l plasma levels , 1992, European journal of clinical investigation.

[9]  R. Derksen,et al.  Lupus Anticoagulant Activity Is Frequently Dependent on the Presence of β2-Glycoprotein I , 1992, Thrombosis and Haemostasis.

[10]  T. Barbui,et al.  Increased Levels of β2-Glycoprotein I (aca-Cofactor) in Patients with Lupus Anticoagulant , 1992, Thrombosis and Haemostasis.

[11]  Y. Shoenfeld,et al.  The beta-2-glycoprotein I and antiphospholipid antibodies. , 1992, Clinical and experimental rheumatology.

[12]  T. Barbui,et al.  Lupus Anticoagulant IgG's (LA) Are Not Directed to Phospholipids only, but to a Complex of Lipid-Bound Human Prothrombin , 1991, Thrombosis and Haemostasis.

[13]  S. Machin,et al.  Guidelines for Testing and Revised Criteria for Lupus Anticoagulants , 1991, Thrombosis and Haemostasis.

[14]  M. Galli,et al.  β2-glycoprotein I for binding of anticardiolipin antibodies to cardiolipin , 1990, The Lancet.

[15]  T. Koike,et al.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease , 1990, The Lancet.

[16]  T. Barbui,et al.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor , 1990, The Lancet.

[17]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Perrino,et al.  Prothrombin-antibody coexistent with lupus anticoagulant (LA): clinical study and immunochemical characterization. , 1990, Thrombosis research.

[19]  S. Rapaport,et al.  Anti-prothrombin antibodies and the lupus anticoagulant. , 1988, Blood.

[20]  D. Simel,et al.  Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. , 1987, The American journal of medicine.

[21]  S. Shapiro,et al.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. , 1986, Blood.

[22]  M. Gardner,et al.  Confidence intervals rather than P values: estimation rather than hypothesis testing. , 1986, British medical journal.

[23]  L. Poller,et al.  The Diagnosis of Lupus Anticoagulants by the Activated Partial Thromboplastin Time - The Central Role of Phosphatidyl Serine , 1984, Thrombosis and Haemostasis.

[24]  D. Hasegawa,et al.  Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. , 1984, Blood.

[25]  D. Fierer,et al.  A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. , 1983, Blood.

[26]  H. Kronenberg,et al.  A Sensitive Test Demonstrating Lupus Anticoagulant and its Behavioural Patterns , 1978, British journal of haematology.

[27]  J. Sedmak,et al.  A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. , 1977, Analytical biochemistry.